Recent News

• 06.17.2025 - Scotiabank Third Annual Healthcare Canadian Investor Day
• 06.13.2025 - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
• 06.09.2025 - Goldman Sachs 46th Annual Healthcare Conference
• 06.04.2025 - Jefferies Global Healthcare Conference
• 06.02.2025 - Zai Lab 2025 ASCO Investor Call
• 06.02.2025 - Zai Lab 2025 ASCO Investor Call
• 06.02.2025 - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
• 05.31.2025 - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
• 05.30.2025 - Zai Lab Announces Participation in Investor Conferences in June 2025
• 05.22.2025 - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Recent Filings

• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2025 - 144 Report of proposed sale of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - 144 Report of proposed sale of securities
• 05.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2025 - 4 Statement of changes in beneficial ownership of securities